Mein Warenkorb

Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*04:01&GAD65 (NFFRMVISNPAAT) Complex Protein (Monomer, MALS verified)

User Reviews
Product Number/Spec
Price
Menge
HL5-H82E6-25ug
$126.00
HL5-H82E6-200ug
$714.00
ETA of in-stock products:2 business days
Gesamtanzahl Product Amount$ 0

Product Details

  • Synonyms

    HLA-DRA1*0101 & HLA-DRB1*0401 & GAD65 (NFFRMVISNPAAT)

  • Source

    Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*04:01&GAD65 (NFFRMVISNPAAT) Complex Protein (HL5-H82E6) is expressed from human 293 cells (HEK293). It contains AA Ile 26 - Glu 216 (HLA-DRA1*01:01) & Gly 30 - Lys 227 (HLA-DRB1*04:01) & NFFRMVISNPAAT peptide (Accession # CAI2388006.1 (HLA-DRA1*01:01) & CAI9239961.1 (HLA-DRB1*04:01) & NFFRMVISNPAAT).

    Predicted N-terminus: Ile 26 & Asn

    Request for sequence
  • Molecular Characterization

    Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*04:01&GAD65 (NFFRMVISNPAAT) Complex Protein is produced by co-expression of HLA-DRA1 and HLA-DRB1 loaded with GAD65 peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 29.6 kDa and 29.2 kDa. The protein migrates as 38-42 kDa and 33-37 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • SDS-PAGE

    HLA-DRA1*0101 & HLA-DRB1*0401 & GAD65 (NFFRMVISNPAAT) SDS-PAGE

    Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*04:01&GAD65 (NFFRMVISNPAAT) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    HLA-DRA1*0101 & HLA-DRB1*0401 & GAD65 (NFFRMVISNPAAT) SEC-MALS

    The purity of Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*04:01&GAD65 (NFFRMVISNPAAT) Complex Protein (Cat. No. HL5-H82E6) is more than 90% and the molecular weight of this protein is around 60-85 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-DRA1*0101 & HLA-DRB1*0401 & GAD65 (NFFRMVISNPAAT) ELISA

    Immobilized Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*04:01&GAD65 (NFFRMVISNPAAT) Complex Protein (Cat. No. HL5-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA-DR Antibody, Human IgG1 with a linear range of 0.03-4 ng/mL (QC tested).

    Protocol

User Reviews
Publish Comment

Background Introduction

The peptide NFFRMVISNPAAT, derived from the human autoantigen glutamic acid decarboxylase 65 (GAD65), is presented by the MHC class II molecule HLA-DRA1*01:01/HLA-DRB1*04:01. This specific peptide-MHC II complex is strongly associated with the genetic risk for type 1 diabetes (T1D), particularly in individuals carrying the HLA-DRB1*04:01 allele. Recognition of this complex by autoreactive CD4⁺ T cells is a pivotal event in the autoimmune attack against pancreatic islet beta cells, making it a critical target for understanding the etiology of T1D and for developing antigen-specific immunotherapies.

Frontier Progress

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • Hintergrund
Kontaktieren Sie uns